Novartis AG ADR (NVS)vsUtah Medical Products Inc (UTMD)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
UTMD
Utah Medical Products Inc
$65.42
+0.60%
HEALTHCARE · Cap: $207.06M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 150646% more annual revenue ($56.58B vs $37.53M). UTMD leads profitability with a 28.9% profit margin vs 23.9%. NVS appears more attractively valued with a PEG of 2.48. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
UTMD
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
-22.8%
Fair Value
$51.90
Current Price
$65.42
$13.52 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Keeps 29 of every $100 in revenue as profit
Reasonable price relative to book value
Strong operational efficiency at 29.4%
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Smaller company, higher risk/reward
Expensive relative to growth rate
Revenue declined 10.2%
Earnings declined 11.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : UTMD
The strongest argument for UTMD centers on Profit Margin, Price/Book, Operating Margin. Profitability is solid with margins at 28.9% and operating margin at 29.4%.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : UTMD
The primary concerns for UTMD are Market Cap, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
NVS carries more volatility with a beta of 0.52 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 46/100), backed by strong 23.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Utah Medical Products Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Utah Medical Products, Inc. develops, manufactures and distributes medical devices for the healthcare industry. The company is headquartered in Midvale, Utah.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?